A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo

Brenna Carey, Monica DeLay, Jane E. Strasser, Claudia Chalk, Kristen Dudley-McClain, Gregg Milligan, Hermine I. Brunner, Sherry Thornton, Raphael Hirsch

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

CD8+ T lymphocytes recognize tumor and viral antigens bound to class I major histocompatibility complexes (MHC). Tumors and viruses may evade detection by preventing antigen presentation. The present study was designed to determine whether a soluble divalent fusion protein, containing the extracellular domains of a class I MHC molecule fused to β2-microglobulin and the constant domains of IgG1, could induce an immune response in vivo. Administration to mice of the fusion protein loaded with a tumor peptide induced peptide-specific T cell activation and retarded tumor growth. Administration of the fusion protein loaded with a glycoprotein B (gB) peptide derived from herpes simplex virus type 1 (HSV-1) induced gB-specific cytotoxic T lymphocytes and protected mice from a lethal HSV-1 challenge. These data suggest that antigen-loaded MHC/IgG fusion proteins may enhance T cell immunity in conditions where antigen presentation is altered.

Original languageEnglish (US)
Pages (from-to)65-76
Number of pages12
JournalClinical Immunology
Volume116
Issue number1
DOIs
StatePublished - Jul 2005

Fingerprint

Major Histocompatibility Complex
Immunoglobulin G
T-Lymphocytes
Antigen Presentation
Human Herpesvirus 1
Proteins
Peptide T
Oncogenic Viruses
Viral Tumor Antigens
Cytotoxic T-Lymphocytes
Immunity
Neoplasms
Glycoproteins
Antigens
Peptides
Growth

Keywords

  • CTL
  • MHC
  • T lymphocytes
  • Tumor immunity
  • Vaccination
  • Viral immunity

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Carey, B., DeLay, M., Strasser, J. E., Chalk, C., Dudley-McClain, K., Milligan, G., ... Hirsch, R. (2005). A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo. Clinical Immunology, 116(1), 65-76. https://doi.org/10.1016/j.clim.2005.02.013

A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo. / Carey, Brenna; DeLay, Monica; Strasser, Jane E.; Chalk, Claudia; Dudley-McClain, Kristen; Milligan, Gregg; Brunner, Hermine I.; Thornton, Sherry; Hirsch, Raphael.

In: Clinical Immunology, Vol. 116, No. 1, 07.2005, p. 65-76.

Research output: Contribution to journalArticle

Carey, B, DeLay, M, Strasser, JE, Chalk, C, Dudley-McClain, K, Milligan, G, Brunner, HI, Thornton, S & Hirsch, R 2005, 'A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo', Clinical Immunology, vol. 116, no. 1, pp. 65-76. https://doi.org/10.1016/j.clim.2005.02.013
Carey, Brenna ; DeLay, Monica ; Strasser, Jane E. ; Chalk, Claudia ; Dudley-McClain, Kristen ; Milligan, Gregg ; Brunner, Hermine I. ; Thornton, Sherry ; Hirsch, Raphael. / A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo. In: Clinical Immunology. 2005 ; Vol. 116, No. 1. pp. 65-76.
@article{58feee01233d4a3b959422b03f7a7a56,
title = "A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo",
abstract = "CD8+ T lymphocytes recognize tumor and viral antigens bound to class I major histocompatibility complexes (MHC). Tumors and viruses may evade detection by preventing antigen presentation. The present study was designed to determine whether a soluble divalent fusion protein, containing the extracellular domains of a class I MHC molecule fused to β2-microglobulin and the constant domains of IgG1, could induce an immune response in vivo. Administration to mice of the fusion protein loaded with a tumor peptide induced peptide-specific T cell activation and retarded tumor growth. Administration of the fusion protein loaded with a glycoprotein B (gB) peptide derived from herpes simplex virus type 1 (HSV-1) induced gB-specific cytotoxic T lymphocytes and protected mice from a lethal HSV-1 challenge. These data suggest that antigen-loaded MHC/IgG fusion proteins may enhance T cell immunity in conditions where antigen presentation is altered.",
keywords = "CTL, MHC, T lymphocytes, Tumor immunity, Vaccination, Viral immunity",
author = "Brenna Carey and Monica DeLay and Strasser, {Jane E.} and Claudia Chalk and Kristen Dudley-McClain and Gregg Milligan and Brunner, {Hermine I.} and Sherry Thornton and Raphael Hirsch",
year = "2005",
month = "7",
doi = "10.1016/j.clim.2005.02.013",
language = "English (US)",
volume = "116",
pages = "65--76",
journal = "Clinical Immunology",
issn = "1521-6616",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo

AU - Carey, Brenna

AU - DeLay, Monica

AU - Strasser, Jane E.

AU - Chalk, Claudia

AU - Dudley-McClain, Kristen

AU - Milligan, Gregg

AU - Brunner, Hermine I.

AU - Thornton, Sherry

AU - Hirsch, Raphael

PY - 2005/7

Y1 - 2005/7

N2 - CD8+ T lymphocytes recognize tumor and viral antigens bound to class I major histocompatibility complexes (MHC). Tumors and viruses may evade detection by preventing antigen presentation. The present study was designed to determine whether a soluble divalent fusion protein, containing the extracellular domains of a class I MHC molecule fused to β2-microglobulin and the constant domains of IgG1, could induce an immune response in vivo. Administration to mice of the fusion protein loaded with a tumor peptide induced peptide-specific T cell activation and retarded tumor growth. Administration of the fusion protein loaded with a glycoprotein B (gB) peptide derived from herpes simplex virus type 1 (HSV-1) induced gB-specific cytotoxic T lymphocytes and protected mice from a lethal HSV-1 challenge. These data suggest that antigen-loaded MHC/IgG fusion proteins may enhance T cell immunity in conditions where antigen presentation is altered.

AB - CD8+ T lymphocytes recognize tumor and viral antigens bound to class I major histocompatibility complexes (MHC). Tumors and viruses may evade detection by preventing antigen presentation. The present study was designed to determine whether a soluble divalent fusion protein, containing the extracellular domains of a class I MHC molecule fused to β2-microglobulin and the constant domains of IgG1, could induce an immune response in vivo. Administration to mice of the fusion protein loaded with a tumor peptide induced peptide-specific T cell activation and retarded tumor growth. Administration of the fusion protein loaded with a glycoprotein B (gB) peptide derived from herpes simplex virus type 1 (HSV-1) induced gB-specific cytotoxic T lymphocytes and protected mice from a lethal HSV-1 challenge. These data suggest that antigen-loaded MHC/IgG fusion proteins may enhance T cell immunity in conditions where antigen presentation is altered.

KW - CTL

KW - MHC

KW - T lymphocytes

KW - Tumor immunity

KW - Vaccination

KW - Viral immunity

UR - http://www.scopus.com/inward/record.url?scp=19544376672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19544376672&partnerID=8YFLogxK

U2 - 10.1016/j.clim.2005.02.013

DO - 10.1016/j.clim.2005.02.013

M3 - Article

C2 - 15925833

AN - SCOPUS:19544376672

VL - 116

SP - 65

EP - 76

JO - Clinical Immunology

JF - Clinical Immunology

SN - 1521-6616

IS - 1

ER -